CN103739553A - N-substituted imidazolecarboxylic acid ester chiral compound containing ether side chain, preparation method and application thereof - Google Patents

N-substituted imidazolecarboxylic acid ester chiral compound containing ether side chain, preparation method and application thereof Download PDF

Info

Publication number
CN103739553A
CN103739553A CN201310716377.2A CN201310716377A CN103739553A CN 103739553 A CN103739553 A CN 103739553A CN 201310716377 A CN201310716377 A CN 201310716377A CN 103739553 A CN103739553 A CN 103739553A
Authority
CN
China
Prior art keywords
compound
formula
preparation
etomidate
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201310716377.2A
Other languages
Chinese (zh)
Other versions
CN103739553B (en
Inventor
张文胜
杨俊�
刘进
唐磊
柯博文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
West China Hospital of Sichuan University
Original Assignee
West China Hospital of Sichuan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West China Hospital of Sichuan University filed Critical West China Hospital of Sichuan University
Priority to CN201310716377.2A priority Critical patent/CN103739553B/en
Publication of CN103739553A publication Critical patent/CN103739553A/en
Priority to PCT/CN2014/089898 priority patent/WO2015096551A1/en
Priority to US15/107,415 priority patent/US9969695B2/en
Priority to CA2933098A priority patent/CA2933098A1/en
Priority to JP2016539968A priority patent/JP2016540795A/en
Priority to KR1020167017220A priority patent/KR20160089516A/en
Priority to SG11201605055SA priority patent/SG11201605055SA/en
Priority to AU2014373186A priority patent/AU2014373186B2/en
Priority to EP14873468.4A priority patent/EP3088394B1/en
Priority to RU2016123144A priority patent/RU2659784C2/en
Application granted granted Critical
Publication of CN103739553B publication Critical patent/CN103739553B/en
Priority to PH12016501246A priority patent/PH12016501246A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to an N-substituted imidazolecarboxylic acid ester chiral compound containing an ether side chain, a preparation method and an application thereof. The structure of the compound is shown in the formula (I). The compound can produce rapid and reversible general anesthesia effect. Animal experiments show rapid and short-acting pharmacological characteristics of the compound, so that the compound can be used as a rapid and short-acting general anesthesia medicine, meanwhile, compared with etomidate, the compound can reduce the inhibition effect on synthesis of adrenal cortical hormone, recovery is rapid and thorough, and the compound has obvious advantages and good application prospect. The only chiral carbon in the structure of the compound must be of R type. An imidazole ring in the structure of the compound has acidifiable N atoms, so that the compound and medicinal salt molecules thereof can be applied to the preparation of central inhibitory medicines which can produce sedative and hypnotic and/or anesthetic effects on animals or persons through veins or paths outside veins.

Description

The N-substituted imidazole carboxylicesters chipal compounds, preparation method and the purposes that contain ether side chain
Technical field
The present invention relates to a kind of N-substituted imidazole carboxylicesters chipal compounds, preparation method and purposes that contains ether side chain.
Background technology
Etomidate, is a kind of listing general intravenous anesthesia medicine for a long time, and the onset time of this medicine is fast, holds time short, is a kind of more satisfactory general intravenous anesthesia medicine.It also has the very outstanding unique pharmacology of cardiovascular stability simultaneously; minimum to being suppressed in the general anesthetic using clinically at present of body circulation in anesthesia; thereby be particularly suitable for cardiac insufficiency patient with operation (J.F.Cotton, Anesthesiology 2009; 111:240).The anesthetic action mechanism of etomidate is clear and definite at present, main by the inhibition acceptor GABA with maincenter ain conjunction with, make this receptor more responsive to inhibitory neurotransmitter GABA, thereby produce anesthetic action.But deep research discovery, etomidate is synthetic also inhibited to the cortin of body, and particularly long continuous infusion is to the inhibition of cortin more obvious (S.S.Husain, Journal of medicinal chemistry 2006; 49:4818-4825).Because self synthesizing of cortin is the important factor of body anti-inflammatory, therefore this shortcoming is unfavorable to the recovery of postoperative patient, and this disadvantageous effect is gradually by clinical research confirmation, the rate of utilization that has caused etomidate reduces gradually with the intensification of this understanding, because medical worker does not wish to have used the patient of etomidate to face in recovering after surgery, does not infect the danger increasing.
Etomidate is mainly realized by suppressing the activity of 11-β hydroxylase the inhibition of cortin, and this enzyme is the synthetic key enzyme of cortin.This side effect of etomidate is relevant with the glyoxaline structure in drug molecule, a N atom in imidazole ring can with 11-β hydroxylase in topological iron atom form complexing, thereby strengthened the combination of drug molecule and enzyme molecule, thereby reach the effect that suppresses 11-β hydroxylase, and its with the binding ability of 11-β hydroxylase than itself and GABA athe binding ability of acceptor is strong 100 times, this with regard to for design not or the imidazole derivative with weak 11-β hydroxylase binding ability brought challenge (Zolle IM, J Med Chem 2008; 51:2244-53).Etomidate is mainly at liver metabolism, along with the carrying out of drug metabolism study, people drawn the curative effect of etomidate and the time/effect curve of side effect (Stuart A.Forman, Anesthesiology 2011; 114 (3): 695-707), this curve shows, after the etomidate of single injection 3 mg/kg, the minimum onset concentration of the blood plasma of its anaesthetic effect is 110 ng/ml, and the time that medicine maintains on this concentration in blood plasma only has 8 min; And etomidate is 8 ng/ml to the synthetic minimum onset concentration suppressing of cortin, medicine in blood plasma, maintain on this concentration for up to 8 h.This show, patient given to the etomidate of anaesthesia dosage, and after anaesthetic effect disappears fast, to cortin, synthetic inhibition also will exist the long period.
Therefore, can retain under the pharmacologically active prerequisite of this medicine, obtain and can not produce the synthetic imidazoles general anesthesia medicine suppressing of obvious cortin, can reduce the side effect of imidazoles general anesthesia medicine, thereby making the range of application of this class medicine more extensive, is very significant.
Summary of the invention
In view of the foregoing, the invention provides a kind of N-substituted imidazole carboxylicesters chipal compounds that contains ether side chain, and the preparation method and its usage of this compound is further provided, can realize satisfactorily above-mentioned object.
The N-substituted imidazole carboxylicesters chipal compounds that the present invention contains ether side chain, comprises acceptable salt compounds in its pharmacy of this chipal compounds.The structure of said N-substituted imidazole carbonate is as shown in formula I, and chirality C* is wherein configured as R type:
Figure 2013107163772100002DEST_PATH_IMAGE002
。
Acceptable salt compounds in the pharmacy of said N-substituted imidazole carboxylicesters chipal compounds, can comprise as conventional salt compounds in the pharmacy such as its hydrochloride, hydrobromate, trifluoroacetate.
Above-claimed cpd of the present invention can be obtained by its DL compound after optical resolution, also can directly prepare.Its basic preparation method, can adopt under polar aprotic solvent and alkaline condition, with the N-substituted imidazole carboxylic acid chipal compounds of formula II and the halogenide of formula III, be substituted after reacting and obtain formula I target compound, the chirality C* in formula is configured as R type, and X is halogen element.Reaction process is as follows:
Figure 2013107163772100002DEST_PATH_IMAGE004
。
On above-mentioned preparation method's basis, can also be separately or the optimal way that adopts with any combination comprise:
Said halogen element X is preferably Br or Cl;
Said reaction solvent is preferably DMF;
Said alkali is preferably the mineral alkali that comprises alkali-metal oxyhydroxide or carbonate.
Therefore owing to thering is salifiable alkaline N atom in formula I compound structure, by above-mentioned prepare or this formula I compound of obtaining through other approach, after acceptable acid group is combined in pharmacy, can obtain corresponding salt compounds.
Experimentation on animals shows, N-substituted imidazole carboxylic acid ester compound and the salt thereof of the above-mentioned formula I structure of the present invention all can produce the pharmacological actions such as quick, reversible tranquilizing soporific and/or anesthesia, single-dose is held time more fugitive than the anaesthetic effect of etomidate, Analepsia quality is better, and can significantly alleviate the inhibition to adrenocortical hormone, recover rapidly and thoroughly.By comparison, the corresponding S type optical isomer (IV) of formula I compound and corresponding raceme (V) are being tired, and safety range aspect is all obviously not so good as the R type compound (comprising said its pharmaceutical salts) of above-mentioned formula I of the present invention.Therefore, acceptable salt compounds in the N-substituted imidazole carboxylic acid esters chipal compounds that the present invention is above-mentioned or its pharmacy, for the preparation of animal or human being produced in the maincenter suppressive drug of tranquilizing soporific and/or anesthetic action as approach outside vein or vein, there is significant advantage, value and application prospect.
Figure 2013107163772100002DEST_PATH_IMAGE006
Below in conjunction with the embodiment by accompanying drawing illustrated embodiment, foregoing of the present invention is described in further detail again.But this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following example.Without departing from the idea case in the present invention described above, various replacements or the change according to ordinary skill knowledge and customary means, made, all should comprise within the scope of the invention.
Accompanying drawing explanation
fig. 1 is that the ee value of embodiment 1 product (formula I compound) detects collection of illustrative plates.
Fig. 2 is that the ee value of embodiment 3 products (formula IV compound) detects collection of illustrative plates.
Fig. 3 is that the ee value of embodiment 4 products (formula (V) compound) detects collection of illustrative plates.
Embodiment
embodiment 1
The preparation of formula I compound of the present invention: by formula II compound (CAS:56649-48-0) (216 mg, 1 mmol), formula III compound (CAS:6482-24-2) (278 mg, 2 mmol) with Anhydrous potassium carbonate (564 mg, 3 mmol) be mixed in 15 mL N, dinethylformamide, mixture spends the night in 50 ℃ of stirring reactions.Pour in 100 mL cold water to obtain settled solution by reaction solution next day, make to be extracted with ethyl acetate 3 times (each 50 mL), merge organic layer, with anhydrous sodium sulfate drying, spend the night, filter to get filtrate, evaporated under reduced pressure solvent obtains oily crude product, through silicagel column purifying (developping agent: cyclohexane/ethyl acetate=3/2) obtain colorless oil 150 mg, productive rate 54%.
1) nuclear-magnetism: instrument: BRUKER, TMS is interior mark.
1H-NMR?(400MHz?CDCl 3)? δ：1.862?(3H,?d,? J=7.2Hz),?3.393(3H,?s),?3.645(3H,?t,? J=4.8Hz),?4.318~4.405?(2H,?m),?6.348(1H,?q,? J=7.2?Hz),?7.176~7.359?(m,?5H),?7.742?(s,?1H),?7.827?(s,?1H).
13C-NMR?(100MHz?CDCl 3)? δ：22.30,?55.48,?59.15,?63.53,?70.48,?122.39,?126.36,?128.08,?128.93,?138.63,?140.02,?141.20,?160.26.
2) mass spectrum: mass spectrograph: the API3000 LC-Ms/Ms of American AB I company, ionization mode: ESI.
(M+H).HRMS:?for?C 15H 18N 2O 3+H,?calcd?275.1396,?found?275.1396.
3) optical value: formula I compound is mixed with to the ethanolic soln that concentration is 1g/100 mL, uses Polarimeter 341 polarimeters to measure its optical value, [α] d 20=+71.9 °.
4) ee value: formula I compound is configured to the methanol solution that concentration is 1 mg/mL, dilutes 100 times of sample introductions.Use chirality AD post to detect through high performance liquid chromatography, UV-detector wavelength: 254 nm detect, moving phase: 20% Virahol-normal hexane, flow velocity: 1 mL/min.After measured, the optical purity of compound (I) reaches 100%.As shown in Figure 1.
embodiment 2
The preparation of formula I compound of the present invention: by formula II compound (CAS:56649-48-0) (216 mg, 1 mmol), formula III compound (CAS:627-42-9) (188 mg, 2 mmol) with Anhydrous potassium carbonate (564 mg, 3 mmol) be mixed in 15 mL N, dinethylformamide, mixture spends the night in 50 ℃ of stirring reactions.Pour in 100 mL cold water to obtain settled solution by reaction solution next day, make to be extracted with ethyl acetate 3 times (each 50 mL), merge organic layer, with anhydrous sodium sulfate drying, spend the night, filter to get filtrate, evaporated under reduced pressure solvent obtains oily crude product, through silicagel column purifying (developping agent: cyclohexane/ethyl acetate=3/2) obtain colorless oil 120 mg, productive rate 43%.
embodiment 3
the preparation of S type optical counterpart compound (IV):
By S-(-)-1-(1-styroyl)-1-hydrogen-imidazoles-5-formic acid (CAS:56649-49-1) 216 mg, 1 mmol), formula III compound (CAS:627-42-9) (188 mg, 2 mmol) with Anhydrous potassium carbonate (564 mg, 3 mmol) be mixed in 15 mL N, dinethylformamide, mixture spends the night in 50 ℃ of stirring reactions.Pour in 100 mL cold water to obtain settled solution by reaction solution next day, make to be extracted with ethyl acetate 3 times (each 50 mL), merge organic layer, with anhydrous sodium sulfate drying, spend the night, filter to get filtrate, evaporated under reduced pressure solvent obtains oily crude product, through silicagel column purifying (developping agent: cyclohexane/ethyl acetate=3/2) obtain colorless oil 170 mg, productive rate 61.2%.
1) nuclear-magnetism: instrument: BRUKER, TMS is interior mark.
1H-NMR?(400MHz?CDCl 3) ?δ：1.859?(3H,?d,? J=7.2Hz),?3.392(3H,?s),?3.644(3H,?t?,? J=4.8Hz),?4.301~4.412?(2H,?m),?6.342(1H,?q,? J=7.2?Hz),?7.172~7.355?(m,?5H),?7.728?(s,?1H),?7.822?(s,?1H).
2) optical value: by formula ( iV) compound is mixed with the ethanolic soln that concentration is 1 g/100 mL, uses Polarimeter 341 polarimeters to measure its optical value, be [α] d 20=-69.3 °.
3) ee value: by formula ( iV) compound is configured to the methanol solution that concentration is 1 mg/mL, dilutes 100 times of sample introductions.Use chirality AD post to detect through high performance liquid chromatography, UV-detector wavelength: 254 nm detect, moving phase: 20% Virahol-normal hexane, flow velocity: 1 mL/min.After measured, compound ( iV) optical purity reach 99%.As shown in Figure 2.
embodiment 4
the preparation of corresponding raceme compound (V):
By (±)-1-(1-styroyl)-1-hydrogen-imidazoles-5-formic acid (CAS:7036-56-8) 216 mg, 1 mmol), formula III compound (CAS:627-42-9) (188 mg, 2 mmol) with Anhydrous potassium carbonate (564 mg, 3 mmol) be mixed in 15 mL N, dinethylformamide, mixture spends the night in 50 ℃ of stirring reactions.Pour in 100 mL cold water to obtain settled solution by reaction solution next day, make to be extracted with ethyl acetate 3 times (each 50 mL), merge organic layer, with anhydrous sodium sulfate drying, spend the night, filter to get filtrate, evaporated under reduced pressure solvent obtains oily crude product, through silicagel column purifying (developping agent: cyclohexane/ethyl acetate=3/2) obtain colorless oil 177 mg, productive rate 63.7%.
1) nuclear-magnetism: instrument: BRUKER, TMS is interior mark.
1HNMR?(300MHz?CDCl 3)? δ：1.839?(3H,?d,? J=7.2Hz),?3.384(3H,?s),?3.619(2H,?t,? J=4.8Hz),?4.284~4.388?(2H,?m),?6.325(1H,?q,? J=7.2?Hz),?7.151~7.344?(m,?5H),?7.749?(s,?1H),?7.806?(s,?1H).
2) ee value: by formula ( v) compound is configured to the methanol solution that concentration is 1 mg/mL, dilutes 100 times of sample introductions.Use chirality AD post to detect through high performance liquid chromatography, UV-detector wavelength: 254 nm, moving phase: 20% Virahol-normal hexane, flow velocity: 1 mL/min.After measured, compound ( v) be the geometric ratio mixture of R and two kinds of configurations of S, i.e. raceme, as shown in Figure 3.
embodiment 5
The product of 2 g embodiment 1 is dissolved in 50 mL anhydrous diethyl ethers, under ice bath, passes into excessive HCl gas, separate out a large amount of white precipitates, after filtering, be dried to obtain white powder 1.97 g, i.e. the hydrochloride of formula I compound.Nuclear-magnetism: instrument: BRUKER, TMS is interior mark.
1HNMR?(300MHz?D 2O) ?δ：1.833?(3H,?d,? J=7.2Hz),?3.378(3H,?s),?3.614(2H,?t,? J=4.8Hz),?4.281~4.392?(2H,?m),?6.321(1H,?q,? J=7.2?Hz),?7.333~7.452?(m,?5H),?8.001?(s,?1H),?9.908?(s,?1H).
embodiment 6
The product of 2 g embodiment 1 is dissolved in 50 mL anhydrous diethyl ethers, under ice bath, drips 10% HBr acetum, separate out a large amount of white precipitates, after filtering, be dried to obtain white powder 2.12 g, i.e. the hydrobromate of formula I compound.Nuclear-magnetism: instrument: BRUKER, TMS is interior mark.
1HNMR?(300MHz?D 2O) ?δ：1.821?(3H,?d,? J=7.2Hz),?3.358(3H,?s),?3.611(2H,?t,? J=4.8Hz),?4.282~4.398?(2H,?m),?6.319(1H,?q,? J=7.2?Hz),?7.343~7.467?(m,?5H),?8.000?(s,?1H),?9.907?(s,?1H).
embodiment 7
The product of 2 g embodiment 1 is dissolved in 50 mL anhydrous diethyl ethers, under ice bath, drips equimolar trifluoracetic acid, separate out a large amount of white precipitates, after filtering, be dried to obtain white powder 1.87 g, i.e. the trifluoroacetate of formula I compound.Nuclear-magnetism: instrument: BRUKER, TMS is interior mark.
1HNMR?(300MHz?D 2O) ?δ：1.842?(3H,?d,? J=7.2Hz),?3.367(3H,?s),?3.609(2H,?t,? J=4.8Hz),?4.271~4.382?(2H,?m),?6.331(1H,?q,? J=7.2?Hz),?7.312~7.432?(m,?5H),?8.011?(s,?1H),?9.928?(s,?1H).
embodiment 8
The male SD rat of body weight 250 ~ 300 g of take is laboratory animal, adopts sequential method to measure median effective dose (ED 50).Three kinds of compounds are all used DMSO as dissolution with solvents, etomidate is used commercial preparation (B BRAUN, Etomidate-Lipuro, 20 mg/10 ml), initial dose is 1 mg/kg, dosage variation ratio is 0.8, measures the ED of formula I, (IV), (V) three kinds of compounds and etomidate 50.The rat sleeping duration of usining is greater than 30 s and as medicine, produces the positive index of anaesthetic effect, and reflection does not disappear and is considered as invalidly, and test-results is calculated ED after producing 4 intersections 50value.Result shows the ED of three kinds of compounds and etomidate 50be respectively 2.10 mg/kg, 7.46mg/kg, 10.38mg/kg and 1.14 mg/kg.Use subsequently these three kinds of compounds and etomidate 2ED separately 50as dose,equivalent, through tail intravenously administrable, measure four groups (formula I, (IV), (V) three kinds of compounds and etomidate, 10 every group) in the preliminary drug effect of rat.Onset immediately after test-results demonstration formula I and etomidate administration, the onset time of formula IV, (V) is 1-2 min slightly slowly, and hold time formula I and etomidate are 5-6 min, and formula IV, (V) they are 10-20 min.But formula IV, (V) obviously increase in kind and the incidence of duration of test untoward reaction.DMSO does not have pharmacological effect, does not observe the generation of untoward reaction yet.The anesthesia onset time of three kinds of compounds and etomidate, hold time and the kind of untoward reaction and incidence in Table 1.
Figure 2013107163772100002DEST_PATH_IMAGE008
Above-mentioned results of animal shows, formula I compound show good tranquilizing soporific and the general anesthesia effect the same as etomidate of R type of the present invention, its S type enantiomer formula IV compound and raceme formula (V) compound show the reduction of tiring, onset time prolongation, the prolongation of holding time, untoward reaction kind and incidence obviously to be increased.
embodiment 9
The male SD rat of body weight 250 ~ 300 g of take is laboratory animal, adopts sequential method to measure median effective dose (ED 50).The hydrochloride of three kinds of compounds is all used physiological saline as dissolution with solvents, etomidate is still used commercial preparation (B BRAUN, Etomidate-Lipuro, 20 mg/10 ml), initial dose is 1 mg/kg, it is still 0.8 that dosage changes ratio, measures the hydrochloride (embodiment 5) of formula I, the trifluoroacetate (embodiment 7) of the hydrobromate (embodiment 6) of formula I, formula I and the ED of etomidate 50.The rat sleeping duration of usining is greater than 30 s and as medicine, produces the positive index of anaesthetic effect, and reflection does not disappear and is considered as invalidly, and test-results is calculated ED after producing 4 intersections 50value.Result shows three kinds of salt of formula I compound and the ED of etomidate 50be respectively 2.58 mg/kg, 3.09mg/kg, 3.61mg/kg and 1.06 mg/kg.Use subsequently these three kinds of salt and the etomidate 2ED separately of formula I compound 50as dose,equivalent, through tail intravenously administrable, measure four groups (trifluoroacetate and the etomidate of the hydrochloride of formula I, the hydrobromate of formula I, formula I, 10 every group) in the preliminary drug effect of rat.All onsets immediately after test-results the demonstration hydrochloride of formula I, the trifluoroacetate of the hydrobromate of formula I, formula I and etomidate administration, it is held time and is respectively 5-7 min, 5-6 min, 4-7 min and 4-8 min.Recovery time is also all at 5-10 min.Between the kind of duration of test untoward reaction and each group of incidence, there is no notable difference.DMSO does not have pharmacological effect, does not observe the generation of untoward reaction yet.The anesthesia onset time of three kinds of salt and etomidate, hold time and the kind of untoward reaction and incidence in Table 2.
Figure 2013107163772100002DEST_PATH_IMAGE010
Above-mentioned results of animal shows, the hydrochloride of the formula I compound of R type of the present invention, hydrobromate, trifluoroacetate is the same with etomidate can show good tranquilizing soporific and general anesthesia effect.
embodiment 10
Select male Beagle dog (10 ± 2 kg) as animal subject, in the Beagle dog serum by ELISA test kit and microplate reader reader after to administration, Kendall compound, Determination of cortisol are measured.20 Beagle dogs are divided into five groups at random, and 4 every group, give respectively, after dexamethasone (0.01 mg/kg), adrenal cortex level in animal body is down to baseline values, now hydrocortisone and Corticosterone Level are as basic value (Baseline).Give subsequently dose,equivalent (2ED 50) (I) compound (2.88 mg/kg), (IV) compound (5.66 mg/kg) and (V) compound (4.12 mg/kg) and positive control medicine etomidate Etomidate-Lipuro (0.8 mg/kg) and equal-volume solvent DMSO.After 10 min, give ACTH(thyroliberin) stimulate, impel the cortex level in animal body to improve, after giving ACTH, 1 h measures two kinds of cortin concentration in animal body, calculate the ratio of cortex horizontal peak and basic value, obtain the multiple that cortin is enhanced, the larger explanation medicine of multiple is lighter to the inhibition of cortin.The multiple that after etomidate, formula I, (IV), (V) compound and DMSO administration stimulate by ACTH, cortin improves is in Table 3.
Three kinds of compound administrations of table 3 improve situation by the post-stimulatory cortin of ACTH
Compound Hydrocortisone improves multiple Kendall compound improves multiple
DMSO 40.25±33.02 33.79±12.4
Etomidate 2.12±0.56 2.53±0.65
Compound (I) 19.88±19.8 11.46±4.30
Compound (IV) 3.32±2.36 1.19±0.87
Compound (V) 5.17±2.28 3.18±1.15
Above-mentioned experiment shows: etomidate can severe inhibition adrenocortical hormone, and self is synthetic, makes the cortex level of animal subject by ACTH, not stimulated and to improve; Although and the raising of the animal of formula I compound group cortin after ACTH stimulates is not as blank group, apparently higher than positive drug etomidate group.Therefore, formula I compound obviously reduces than control drug etomidate the inhibition of cortin.Formula I compound and formula IV, (V) Compound Phase ratio, also obviously reduce the retarding effect of adrenocortical hormone.
embodiment 11
Select male Beagle dog (10 ± 2 kg) as animal subject, in the Beagle dog serum by ELISA test kit and microplate reader reader after to administration, Kendall compound, Determination of cortisol are measured.20 Beagle dogs are divided into five groups at random, and 4 every group, give respectively, after dexamethasone (0.01 mg/kg), adrenal cortex level in animal body is down to baseline values, now hydrocortisone and Corticosterone Level are as basic value (Baseline).Give subsequently dose,equivalent (2ED 50) hydrochloride (3.62 mg/kg), hydrobromate (3.86 mg/kg), trifluoroacetate (4.66 mg/kg) and positive control medicine etomidate Etomidate-Lipuro (0.9 mg/kg) and the equal-volume solvent DMSO of formula I compound.After 10 min, give ACTH(thyroliberin) stimulate, impel the cortex level in animal body to improve, after giving ACTH, 1 h measures two kinds of cortin concentration in animal body, calculate the ratio of cortex horizontal peak and basic value, obtain the multiple that cortin is enhanced, the larger explanation medicine of multiple is lighter to the inhibition of cortin.The multiple that after three kinds of salt of etomidate, formula I compound and DMSO administration stimulate by ACTH, cortin improves is in Table 4.
Three kinds of salt administrations of table 4 formula I compound improve situation by the post-stimulatory cortin of ACTH
Compound Hydrocortisone improves multiple Kendall compound improves multiple
DMSO 41.26±28.64 30.24±10.38
Etomidate 2.46±0.87 2.80±0.76
The hydrochloride of compound (I) 25.36±14.77 18.14±5.66
The hydrobromate of compound (I) 29.14±11.86 12.36±6.65
The trifluoroacetate of compound (I) 26.14±13.89 13.64±4.22
Above-mentioned experiment shows: etomidate still can severe inhibition adrenocortical hormone, and self is synthetic, makes the cortex level of animal subject by ACTH, not stimulated and to improve; Although and the raising of the animal of the hydrochloride of formula I compound, hydrobromate, trifluoroacetate group cortin after ACTH stimulates is not as blank group, apparently higher than positive drug etomidate group.Therefore, the retarding effect of the salt pair cortin of formula I compound obviously reduces than control drug etomidate.

Claims (8)

1. contain acceptable salt compounds in the N-substituted imidazole carboxylicesters chipal compounds of ether side chain or its pharmacy, the structure of said N-substituted imidazole carbonate is as shown in formula I, and chirality C* is wherein configured as R type:
Figure 2013107163772100001DEST_PATH_IMAGE002
。
2. compound claimed in claim 1, is characterized in that in said pharmacy, acceptable salt compounds comprises hydrochloride, hydrobromate, trifluoracetic acid.
3. the preparation method of compound described in claim 1, it is characterized in that under polar aprotic solvent and alkaline condition, with the N-substituted imidazole carboxylic acid chipal compounds of formula II and the halogenide of formula III, after following substitution reaction, obtain formula I target compound, chirality C* in formula is configured as R type, X is halogen element, and reaction process is as follows:
Figure 2013107163772100001DEST_PATH_IMAGE004
。
4. the preparation method of claim 3, is characterized in that said halogen element X is Br or Cl.
5. the preparation method of claim 3, is characterized in that said reaction solvent is DMF.
6. the preparation method of claim 3, is characterized in that said alkali is the mineral alkali that comprises alkali-metal oxyhydroxide or carbonate.
7. the preparation method who contains acceptable salt compounds in the pharmacy of N-substituted imidazole carboxylicesters chipal compounds of ether side chain described in claim 1 or 2, is characterized in that can obtaining corresponding salt compounds after formula I compound acceptable acid group in pharmacy is combined.
8. the application of acceptable salt compounds in preparing the maincenter suppressive drug that as approach outside vein or vein, animal or human is produced tranquilizing soporific and/or anesthetic action in N-substituted imidazole carboxylic acid esters chipal compounds claimed in claim 1 or its pharmacy.
CN201310716377.2A 2013-12-23 2013-12-23 N-substituted imidazolecarboxylic acid ester chiral compound containing ether side chain, preparation method and application thereof Active CN103739553B (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN201310716377.2A CN103739553B (en) 2013-12-23 2013-12-23 N-substituted imidazolecarboxylic acid ester chiral compound containing ether side chain, preparation method and application thereof
SG11201605055SA SG11201605055SA (en) 2013-12-23 2014-10-30 N-substituted imidazole carboxylic ester chiral compound containing ether side chain, preparation method and application
EP14873468.4A EP3088394B1 (en) 2013-12-23 2014-10-30 Chiral methoxyethyl etomidate compound, its prepartion and application as anesthesia
CA2933098A CA2933098A1 (en) 2013-12-23 2014-10-30 N-substituted imidazole carboxylic ester chiral compound containing an ether side chain, its preparation and application
JP2016539968A JP2016540795A (en) 2013-12-23 2014-10-30 Chiral N-substituted imidazole carboxyl ester compound having ether side chain, its production method and use
KR1020167017220A KR20160089516A (en) 2013-12-23 2014-10-30 N-substituted imidazole carboxylic ester chiral compound containing ether side chain, preparation method and application
PCT/CN2014/089898 WO2015096551A1 (en) 2013-12-23 2014-10-30 N-substituted imidazole carboxylic ester chiral compound containing ether side chain, preparation method and application
AU2014373186A AU2014373186B2 (en) 2013-12-23 2014-10-30 N-substituted imidazole carboxylic ester chiral compound containing ether side chain, preparation method and application
US15/107,415 US9969695B2 (en) 2013-12-23 2014-10-30 N-substituted imidazole carboxylic ester chiral compound containing an ether side chain, its preparation and application
RU2016123144A RU2659784C2 (en) 2013-12-23 2014-10-30 (n-substituted imidazole)-carboxylic ester chiral compound containing ether side chain, preparation method and application
PH12016501246A PH12016501246A1 (en) 2013-12-23 2016-06-23 N-substituted imidazole carboxylic ester chiral compound containing an ether side chain, its preparation and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310716377.2A CN103739553B (en) 2013-12-23 2013-12-23 N-substituted imidazolecarboxylic acid ester chiral compound containing ether side chain, preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN103739553A true CN103739553A (en) 2014-04-23
CN103739553B CN103739553B (en) 2014-11-12

Family

ID=50496641

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310716377.2A Active CN103739553B (en) 2013-12-23 2013-12-23 N-substituted imidazolecarboxylic acid ester chiral compound containing ether side chain, preparation method and application thereof

Country Status (11)

Country Link
US (1) US9969695B2 (en)
EP (1) EP3088394B1 (en)
JP (1) JP2016540795A (en)
KR (1) KR20160089516A (en)
CN (1) CN103739553B (en)
AU (1) AU2014373186B2 (en)
CA (1) CA2933098A1 (en)
PH (1) PH12016501246A1 (en)
RU (1) RU2659784C2 (en)
SG (1) SG11201605055SA (en)
WO (1) WO2015096551A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015096551A1 (en) * 2013-12-23 2015-07-02 四川大学华西医院 N-substituted imidazole carboxylic ester chiral compound containing ether side chain, preparation method and application
WO2017059827A1 (en) * 2015-10-10 2017-04-13 江苏恩华络康药物研发有限公司 Etomidate derivative and intermediate, preparation method and use thereof
CN107382870A (en) * 2016-05-17 2017-11-24 四川海思科制药有限公司 N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine
CN107445898A (en) * 2016-05-30 2017-12-08 四川海思科制药有限公司 N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine
CN107522662A (en) * 2016-06-16 2017-12-29 四川海思科制药有限公司 N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine
CN107641105A (en) * 2016-07-22 2018-01-30 四川海思科制药有限公司 N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine
CN109776512A (en) * 2018-01-30 2019-05-21 成都安诺晨创医药科技有限公司 A kind of N- substituted imidazole formate ester derivative and application thereof
CN110922361A (en) * 2019-11-21 2020-03-27 武汉大安制药有限公司 Etomidate oxidation impurity and preparation method thereof
CN112174890A (en) * 2020-10-09 2021-01-05 成都麻沸散医药科技有限公司 Ketone-substituted heterocyclic compounds and their anesthetic action

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102046607A (en) * 2008-03-31 2011-05-04 通用医疗公司 Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354173A (en) * 1964-04-16 1967-11-21 Janssen Pharmaceutica Nv Imidazole carboxylates
US4770689A (en) * 1986-03-10 1988-09-13 Janssen Pharmaceutica N.V. Herbicidal imidazole-5-carboxylic acid derivatives
CN103588757B (en) * 2013-01-04 2014-11-12 四川大学华西医院 N-substituted imidazole carboxylic ester compound with ultrashort-acting anesthetic effect, preparation method and use thereof
CN103739553B (en) * 2013-12-23 2014-11-12 四川大学华西医院 N-substituted imidazolecarboxylic acid ester chiral compound containing ether side chain, preparation method and application thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102046607A (en) * 2008-03-31 2011-05-04 通用医疗公司 Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOSEPH F. COTTEN, M.D., PH.D: "Methoxycarbonyl-etomidate: A Novel Rapidly Metabolized and Ultra-Short Acting Etomidate Analogue That Does Not Produce Prolonged Adrenocortical Suppression", 《ANESTHESIOLOGY》 *
MARIA ERLANDSSON: "Synthesis and in vitro evaluation of 18F-labelled di- and tri(ethylene glycol) metomidate esters", 《JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS》 *
RI LE GE, M.D., PH.D: "Pharmacological Studies of Methoxycarbonyl Etomidate"s Carboxylic Acid Metabolite", 《ANESTH ANALG》 *
S. SHAUKAT HUSAIN, D.PHIL.: "Modifying Methoxycarbonyl Etomidate’s Inter-Ester Spacer Optimizes In Vitro Metabolic Stability and In Vivo Hypnotic Potency and Duration of Action", 《ANESTHESIOLOGY》 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015096551A1 (en) * 2013-12-23 2015-07-02 四川大学华西医院 N-substituted imidazole carboxylic ester chiral compound containing ether side chain, preparation method and application
CN108349906A (en) * 2015-10-10 2018-07-31 江苏恩华络康药物研发有限公司 Etomidate derivative and its intermediate, preparation method and purposes
WO2017059827A1 (en) * 2015-10-10 2017-04-13 江苏恩华络康药物研发有限公司 Etomidate derivative and intermediate, preparation method and use thereof
CN108349906B (en) * 2015-10-10 2021-11-02 江苏恩华络康药物研发有限公司 Etomidate derivative and intermediate, preparation method and application thereof
US10392352B2 (en) 2015-10-10 2019-08-27 Jiangsu Nhwaluokang Pharmceutical Research And Development Co., Ltd. Etomidate derivative and intermediate, preparation method and use thereof
CN107382870A (en) * 2016-05-17 2017-11-24 四川海思科制药有限公司 N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine
CN107445898A (en) * 2016-05-30 2017-12-08 四川海思科制药有限公司 N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine
CN107522662A (en) * 2016-06-16 2017-12-29 四川海思科制药有限公司 N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine
CN107641105A (en) * 2016-07-22 2018-01-30 四川海思科制药有限公司 N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine
CN109776512A (en) * 2018-01-30 2019-05-21 成都安诺晨创医药科技有限公司 A kind of N- substituted imidazole formate ester derivative and application thereof
CN110922361A (en) * 2019-11-21 2020-03-27 武汉大安制药有限公司 Etomidate oxidation impurity and preparation method thereof
CN110922361B (en) * 2019-11-21 2021-01-08 武汉大安制药有限公司 Etomidate oxidation impurity and preparation method thereof
CN112174890A (en) * 2020-10-09 2021-01-05 成都麻沸散医药科技有限公司 Ketone-substituted heterocyclic compounds and their anesthetic action

Also Published As

Publication number Publication date
JP2016540795A (en) 2016-12-28
EP3088394B1 (en) 2018-12-05
US9969695B2 (en) 2018-05-15
KR20160089516A (en) 2016-07-27
CA2933098A1 (en) 2015-07-02
EP3088394A4 (en) 2017-05-10
EP3088394A1 (en) 2016-11-02
WO2015096551A1 (en) 2015-07-02
RU2016123144A (en) 2018-01-30
CN103739553B (en) 2014-11-12
RU2659784C2 (en) 2018-07-04
RU2016123144A3 (en) 2018-04-27
AU2014373186A1 (en) 2016-07-14
PH12016501246A1 (en) 2016-08-15
SG11201605055SA (en) 2016-09-29
AU2014373186B2 (en) 2017-11-23
US20170001963A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
CN103739553B (en) N-substituted imidazolecarboxylic acid ester chiral compound containing ether side chain, preparation method and application thereof
ES2837431T3 (en) Cystic fibrosis transmembrane conductance regulator modulators, pharmaceutical compositions, treatment methods, and processes for making the modulator
WO2013029431A1 (en) Benzodiazepine derivatives tosylate salts, their polymorphic forms, preparation methods and uses thereof
CN105153122A (en) [(indole-3-yl)pyrimidine-2-yl]aminophenylpropyl-2-eneamide derivative and its salt, preparation method of derivative, and application of derivative and salt
CN106478502B (en) 1,2,3, 4-tetrahydroisoquinoline derivatives, preparation method and application thereof
KR102418211B1 (en) Inhibition of transient receptor potential A1 ion channels
CN113227093A (en) Crystalline spiro compounds, dosage forms comprising the compounds, methods for treatment of disease, and methods of recrystallization
CN104903290A (en) Novel compound having ability to inhibit 11beta-HSD1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
CN104507898B (en) Phenol derivatives and preparation method thereof and application in medicine
WO2018121774A1 (en) Compound for selectively inhibiting kinase and use thereof
CN114948953A (en) Heteroatom substituted aromatic compound and application of salt thereof
CA2955379A1 (en) Methods and compositions for treating hiv-related disorders
ES2914526T3 (en) Biaryl Compositions and Methods for Modulating a Kinase Cascade
CN103058972A (en) Phenyl C-glucoside derivatives containing cyclohexane structure as well as preparation method and application thereof
JP7096559B2 (en) Triptolide derivatives and their manufacturing methods and uses
CN110452229A (en) Deuterated Defactinib compound and application thereof
ITMI20120923A1 (en) INHIBITORS OF CERAMIDASIS ACID AND THEY USE AS MEDICATIONS
CN102241636A (en) Derivative of ligustrazine
CN101786992A (en) 2-hydroxymethyl-3,5,6-trimethylpyrazine derivatives, preparation methods and application thereof
CN113274390A (en) Application of pimavanserin in preparation of antitumor drugs
CN110655490A (en) Halogenated imidazole compounds, preparation method and application
CN112876408B (en) Short-acting bis-quaternary ammonium compound and preparation method and application thereof
CN104230932A (en) Matrine derivatives as well as preparation method and application of matrine derivatives
TW201400470A (en) 4-alkanoylamino-3-pyrazolone derivatives
CN109928959A (en) Drug, preparation method and the purposes of resisting cardiac hypertrophy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20140423

Assignee: Chengdu Lisite Pharmaceutical Co., Ltd.

Assignor: West China Hospital of Sichuan University

Contract record no.: 2018510000014

Denomination of invention: N-substituted imidazolecarboxylic acid ester chiral compound containing ether side chain, preparation method and application thereof

Granted publication date: 20141112

License type: Exclusive License

Record date: 20180320

EE01 Entry into force of recordation of patent licensing contract